Research has shown that at least 60% dopamine occupancy is required to achieve clinically responsive antipsychotic efficacy when treating schizophrenia,33 and higher doses of lurasidone (over 80 mg) achieves better dopamine D2 receptor occupancy levels.40 The gene discussed is DRD2; the disease is schizophrenia.